Paul R. Fortin
Chercheur universitaire clinicien
Axe Maladies infectieuses et immunitaires
Publications
Voir tout-
article Yelnik CM, Erton ZB, Drumez E, Cheildze D, de Andrade D, Clarke A, Tektonidou MG, Sciascia S, Pardos-Gea J, Pengo V, Ruiz-Irastorza G, Belmont HM, Pedrera CL, Fortin PR, Wahl D, Gerosa M, Kello N, Signorelli F, Atsumi T, Ji L, Efthymiou M, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri M, Cervera R, Shi H, Zuo Y, Artim-Esen B, Pons-Estel G, Willis R, Barber MRW, Skeith L, Bertolaccini ML, Cohen H, Roubey R, Erkan D
Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clini…
Semin Arthritis Rheum 65 2024.
-
article Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Lopez-Pedrera C, Fortin PR, Wahl D, Gerosa M, de Jesús GR, Ji L, Atsumi T, Efthymiou M, Branch DW, Nalli C, Rodriguez Almaraz E, Petri M, Cervera R, Knight JS, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Roubey R, Erkan D, de Andrade DCO and
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry
Rheumatology (Oxford) 63 (3), 2024.
-
article Barber MRW, Ugarte-Gil MF, Hanly JG, Urowitz MB, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Pons-Estel BA, Cardwell FS, Alarcón GS, Clarke AE
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Ann Rheum Dis 83 (10), 2024.
Projets
- Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, du 2019-07-01 au 2026-06-30
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, du 2020-04-01 au 2025-03-31
- FcgRI as a potential therapeutic target in inflammatory arthritis, du 2022-01-01 au 2025-03-31
- Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, du 2023-01-01 au 2025-12-31
- Role of megakaryocytes in Systemic Lupus Erythematosus, du 2023-04-01 au 2028-03-31
- Risk stratification and personalized therapy in lupus pregnancies, du 2022-10-01 au 2027-09-30
- Mitochondrial mArkers To Characterize Heterogeneity in SLE (MATCH-SLE) (Planning grant), du 2024-12-01 au 2025-02-28
- Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., du 2015-07-01 au 2023-03-31
- Hydroxychloroquine in systemic lupus, du 2018-04-01 au 2023-03-31
- Understanding the pathogenesis of COVID-19, du 2020-03-01 au 2023-02-28
- The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, du 2020-04-01 au 2023-03-31
- Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , du 2020-12-15 au 2023-03-31
- COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, du 2021-03-16 au 2023-03-31
- Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , du 2021-04-01 au 2023-09-30
- Megakaryocyte: a new player in systemic lupus erythematosus, du 2022-09-01 au 2023-08-31